Radioactive drug lutathera tested against Hard-to-Treat meningioma
NCT ID NCT06955169
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether the radioactive drug Lutathera can slow or stop the growth of progressive meningioma, a type of brain tumor. About 153 adults with grade 1-3 meningioma will be randomly assigned to receive Lutathera or standard treatments like bevacizumab or everolimus. The study is currently suspended, and researchers are measuring how long participants live without their disease getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (177Lu-DOTATATE)
What this could lead to
If successful, this could offer a new treatment option for people with progressive meningioma that has not responded to standard therapies.
What could go wrong
This is an early-phase (Phase 2) trial with a small number of participants. The study is currently suspended, and it is unknown if Lutathera will prove more effective than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRACRANIAL MENINGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Health Medical Group Oncology
Miami, Florida, 33176, United States
-
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207, United States
-
Dana-Farber/Harvard Cancer Center
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 22708, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
NYU Lagone Health
New York, New York, 10016, United States
-
Piedmont Healthcare
Atlanta, Georgia, 30318, United States
-
University of California San Diego - Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California, Irvine
Irvine, California, 92697, United States
-
University of Miami
Miami, Florida, 33146, United States
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Yale University
New Haven, Connecticut, 06520, United States